Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cutanix
Newark, Delaware, United Statescutanix.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Cutanix is a biopharmaceutical company dedicated to the development of innovative topical therapies for inflammatory dermatological conditions. The company's core technology is based on Quadrinone, a proprietary small molecule that acts as a selective inhibitor of the inflammatory response. This technology was specifically designed to treat skin disorders like rosacea, atopic dermatitis, and psoriasis without the adverse effects typically seen with topical steroids. Cutanix successfully launched the Dermalex line of products, which utilized Quadrinone to reduce skin redness and irritation. In 2012, the company was acquired by Suneva Medical, which integrated Cutanix's anti-inflammatory technology into its aesthetic and dermatological portfolio.
- Therapeutic areas
- Dermatology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Cutanix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cutanix.